ADA-HF: acetazolamide as a chloride sparing diuretic in patients admitted to hospital with heart failure.
J J Cuthbert, E Luo, A S M Ahmed et al.
✦ AI-curated · Sources linked
In 30 seconds
The ADA-HF study evaluated the effects of oral acetazolamide (ACZ) on diuresis and chloride loss in hospitalized heart failure patients. In this single-centre, randomized controlled trial involving 46 patients, ACZ did not significantly increase daily net fluid loss compared to standard care (1073 mL vs. 1029 mL, P=0.51), but it effectively spared chloride levels, which fell by 7 mmol/L in the standard care group (P<0.001).
Key findings
- Daily net fluid loss was 1073 mL in the ACZ group vs. 1029 mL in the SoC group (P=0.51).
- Serum chloride concentration fell by 7 mmol/L in the SoC group (P<0.001), but not in the ACZ group.
- Adverse events were numerically higher in the ACZ group, with 51 events in 16 patients.
Why it matters
Understanding the effects of adjunctive therapies like acetazolamide in heart failure management is crucial, especially regarding diuretic efficacy and electrolyte balance. This study highlights the potential for chloride-sparing benefits while raising concerns about side effects.